Anzeige
Mehr »
Donnerstag, 26.06.2025 - Börsentäglich über 12.000 News
Ein echter Gamechanger: Diese News kann den Grundstein für eine Neubewertung der Rock-Tech-Aktie legen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E4YX | ISIN: US70261F2020 | Ticker-Symbol:
NASDAQ
26.06.25 | 16:50
0,723 US-Dollar
+1,77 % +0,013
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PASITHEA THERAPEUTICS CORP Chart 1 Jahr
5-Tage-Chart
PASITHEA THERAPEUTICS CORP 5-Tage-Chart

Aktuelle News zur PASITHEA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrPasithea Therapeutics Corp. - 8-K, Current Report2
11.06.Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board1
02.06.Pasithea reports promising phase 1 results for cancer drug1
02.06.Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025100-- PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid tumors -- -- One patient in cohort 4A (15mg capsule) with stage 4 BRAF-mutated...
► Artikel lesen
20.05.Pasithea Announces Strong Preclinical Results For PAS-004 In Inflammatory Disease Model-
20.05.Pasithea's PAS-004 shows promise in inflammatory disease study1
20.05.PAS-004 von Pasithea zeigt vielversprechende Ergebnisse in Studie zu Entzündungskrankheiten1
PASITHEA THERAPEUTICS Aktie jetzt für 0€ handeln
20.05.Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases3
15.05.Pasithea Therapeutics Corp. - 10-Q, Quarterly Report1
14.05.Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site144-- First patient expected to be dosed during Q2 2025 ---- Trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in both plexiform neurofibromas and...
► Artikel lesen
07.05.Pasithea Therapeutics Corp. - 8-K, Current Report3
07.05.Pasithea Therapeutics Announces Closing of $5 Million Public Offering4
06.05.Pasithea Therapeutics Announces Pricing of $5 Million Public Offering4
06.05.Pre-market Movers: Marin Software, Pasithea Therapeutics, China SXT Pharmaceuticals, Tactile Systems Technology, ThredUp501BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 09.00 A.M. ET).In the Green Marin Software Incorporated (MRIN) is up over 141%...
► Artikel lesen
06.05.Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results5
06.05.Pasithea berichtet über vielversprechende Daten zu Krebsmedikament PAS-00410
06.05.Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004127-- PAS-004 shows up to 91% inhibition of pERK, confirming substantial target engagement -- -- One patient in cohort 4A with stage 4 KRAS G12R mutated pancreatic cancer achieves over 5 months of stable...
► Artikel lesen
01.05.Pasithea Therapeutics Corp. - S-1, General form for registration of securities3
29.04.Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients219MIAMI, April 29, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic...
► Artikel lesen
25.04.Pasithea Therapeutics Corp. - 8-K, Current Report1
Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1